Uncertainty in R&D Outcomes and Securing and Developing Highly Skilled Personnel
First written in FY2016. 18 of 19 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2026: 17 of 35 companies on the "Worse" side.
82 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「The group's total research and development expenses during the interim consolidated accounting period were ¥476.097 million. There were no material changes in the status of the group's research and development activities during the interim consolidated accounting period.」
Regarding the traditional risks associated with uncertainty over R&D results and reliance on highly skilled technical personnel, the company states that there have been no significant changes in its R&D activities and discloses R&D expenses of ¥476.097 million. - FY2025-H1RestatedAnnual report
「The Group's total R&D expenses for the interim consolidated accounting period were ¥490.545 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
The report states that there were no material changes in R&D activities and discloses R&D expenses of ¥490.545 million for the interim consolidated accounting period. - FY2022RestatedAnnual report
「There is a risk that R&D results are uncertain and may not necessarily lead to successful outcomes. In addition, the Group's growth depends particularly on capable personnel involved in R&D, making it important to recruit and develop personnel with strong technical skills and to evaluate research results appropriately.」
The report reiterates the risks associated with uncertainty surrounding R&D results and the recruitment and development of highly skilled technical personnel. R&D expenses were ¥844.896 million. - FY2022-Q3RestatedAnnual report
「The Group's total R&D expenses for the first nine months of the fiscal year under review were ¥604.424 million. There were no material changes in the status of the Group's R&D activities during the first nine months of the fiscal year under review.」
The report discloses R&D expenses of ¥604.424 million and reconfirms that there were no material changes in the status of R&D activities. - FY2022-Q2RestatedAnnual report
「The Group's total R&D expenses for the first six months of the fiscal year under review were ¥394.252 million. There were no material changes in the status of the Group's R&D activities during the first six months of the fiscal year under review.」
The report states that there were no material changes in R&D activities and discloses R&D expenses of ¥394.252 million for the first six months of the fiscal year under review. - FY2022-Q1RestatedAnnual report
「The Group's total R&D expenses for the first three months of the fiscal year under review were ¥196.633 million. There were no material changes in the status of the Group's R&D activities during the first three months of the fiscal year under review.」
The report states that there were no material changes in R&D activities and discloses R&D expenses of ¥196.633 million for the first three months of the fiscal year under review. - FY2021-Q3RestatedAnnual report
「The Group's total R&D expenses for the first nine months of the fiscal year under review were ¥561.539 million. There were no material changes in the status of the Group's R&D activities during the first nine months of the fiscal year under review.」
The report states that there were no material changes in R&D activities and discloses cumulative R&D expenses of ¥561.539 million. - FY2021-Q2RestatedAnnual report
「The Group's total R&D expenses for the first six months of the fiscal year under review were ¥374.159 million. There were no material changes in the status of the Group's R&D activities during the first six months of the fiscal year under review.」
The report states that there were no material changes in R&D activities and discloses cumulative R&D expenses of ¥374.159 million. - FY2021-Q1RestatedAnnual report
「The Group's total R&D expenses for the first three months of the fiscal year under review were ¥179.030 million. There were no material changes in the status of the Group's R&D activities during the first three months of the fiscal year under review.」
The report states that there were no material changes in R&D activities and discloses R&D expenses of ¥179.030 million for the first three months of the fiscal year under review. - FY2020-Q3RestatedAnnual report
「The Group's total R&D expenses for the first nine months of the fiscal year under review were ¥547.518 million. There were no material changes in the status of the Group's R&D activities during the first nine months of the fiscal year under review.」
The report states that there were no material changes in R&D activities and discloses cumulative R&D expenses of ¥547.518 million. - FY2020-Q2RestatedAnnual report
「The Group's total R&D expenses for the first six months of the fiscal year under review were ¥368.333 million. There were no material changes in the status of the Group's R&D activities during the first six months of the fiscal year under review.」
The report states that there were no material changes in R&D activities and discloses R&D expenses of ¥368.333 million for the first six months of the fiscal year under review. - FY2019-Q2RestatedAnnual report
「The Group's total R&D expenses for the first six months of the fiscal year under review were ¥407.848 million. There were no material changes in the status of the Group's R&D activities during the first six months of the fiscal year under review.」
The report states that there were no material changes in R&D activities and discloses R&D expenses of ¥407.848 million for the first six months of the fiscal year under review. - FY2019-Q1RestatedAnnual report
「The Group's total R&D expenses for the first three months of the fiscal year under review were ¥199.903 million. There were no material changes in the status of the Group's R&D activities during the first three months of the fiscal year under review.」
The report states that there were no material changes in R&D activities and discloses R&D expenses of ¥199.903 million for the first three months of the fiscal year under review. - FY2018RestatedAnnual report
「There is a risk that R&D results are uncertain and may not necessarily lead to successful outcomes. In addition, the Group's growth depends particularly on capable personnel involved in R&D, making it important to recruit and develop personnel with strong technical skills and to evaluate research results appropriately.」
The report reiterates the risks associated with uncertainty surrounding R&D results and the recruitment and development of technical personnel. It discloses R&D expenses of ¥894.081 million. - FY2018-Q3RestatedAnnual report
「The Group's total R&D expenses for the first nine months of the fiscal year under review were ¥647.261 million. There were no material changes in the status of the Group's R&D activities during the first nine months of the fiscal year under review.」
The report states that there were no material changes in R&D activities and discloses cumulative R&D expenses of ¥647.261 million. - FY2018-Q2RestatedAnnual report
「The Group's total R&D expenses for the first six months of the fiscal year under review were ¥430.029 million. There were no material changes in the status of the Group's R&D activities during the first six months of the fiscal year under review.」
The report states that there were no material changes in R&D activities and discloses R&D expenses of ¥430.029 million for the first six months of the fiscal year under review. - FY2017RestatedAnnual report
「There is a risk that R&D results are uncertain and may not necessarily lead to successful outcomes. In addition, the Group's growth depends particularly on capable personnel involved in R&D, making it important to recruit and develop personnel with strong technical skills and to evaluate research results appropriately.」
The report reiterates the risks associated with uncertainty surrounding R&D results and the recruitment and development of technical personnel. R&D expenses increased to ¥944.821 million. - FY2017-Q3RestatedAnnual report
「The Group's total R&D expenses for the first nine months of the fiscal year under review were ¥689.308 million. There were no material changes in the status of the Group's R&D activities during the first nine months of the fiscal year under review.」
The report states that there were no material changes in R&D activities and discloses cumulative R&D expenses of ¥689.308 million. - FY2016First statedAnnual report
「There is a risk that R&D results are uncertain and may not necessarily lead to successful outcomes. In addition, the Group's growth depends particularly on capable personnel involved in R&D, making it important to recruit and develop personnel with strong technical skills and to evaluate research results appropriately.」
The report states that R&D expenses were ¥871.818 million in the fiscal year ended March 2016, while identifying the risk that results may not be achieved and the risks associated with recruiting and developing technical personnel.